Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Pulm Pharmacol Ther ; 21(3): 516-21, 2008.
Article in English | MEDLINE | ID: mdl-18249145

ABSTRACT

Sildenafil has been widely used as an orphan drug for several years, mostly at a dose of 50mg tid. Since a recent randomized study showed no dose-response relationship, the target dose in future will be 20mg tid. This might, however, have a negative effect on patients being already on 50mg tid. During the past years we usually up-titrated the sildenafil dosage in monthly intervals from 12.5 to 25mg, and then finally to 50mg tid. Therefore, we wondered if a dose-response relationship could be found in a group of 23 patients, in whom we had measured a 6-min walking distance (6-MWD) at all time points. The 6-MWD was virtually unchanged during the treatment with sildenafil 12.5 and 25mg tid, respectively. However, there was a significant improvement by 34+/-63 and 26+/-47m in the 6-MWD after increasing the sildenafil dose to 50mg tid compared with baseline (p=0.015) and 25mg tid (p=0.014), respectively. In conclusion, these data suggest that sildenafil has a clinically relevant dose-response relationship with a significant improvement in 6-MWD only at a dose of 50mg tid.


Subject(s)
Exercise/physiology , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/physiopathology , Phosphodiesterase Inhibitors/therapeutic use , Piperazines/therapeutic use , Sulfones/therapeutic use , Vasodilator Agents/therapeutic use , Aged , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Bosentan , Dose-Response Relationship, Drug , Female , Heart Rate/drug effects , Humans , Hypertension, Pulmonary/psychology , Male , Middle Aged , Oxygen Consumption/drug effects , Purines/therapeutic use , Quality of Life , Sildenafil Citrate , Sulfonamides/therapeutic use , Treatment Outcome , Walking/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...